Neil Gallagher's Insider Trades & SAST Disclosures
Neil Gallagher's most recent trade in Foghorn Therapeutics Inc was a trade of 50,000 Stock Options (Right to buy) done . Disclosure was reported to the exchange on May 1, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Neil Gallagher.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Foghorn Therapeutics Inc | Neil Gallagher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 50,000 | 50,000 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Neil Gallagher | President, Head of R&D | Sale of securities on an exchange or to another person at price $ 15.50 per share. | 10 Feb 2025 | 4,618 | 85,095 (0%) | 0% | 15.5 | 71,597 | Common Stock |
| Syndax Pharmaceuticals Inc | Neil Gallagher | President, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 110,500 | 110,500 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Neil Gallagher | President, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 23,400 | 89,713 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Neil Gallagher | President, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2025 | 18,500 | 66,313 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Gallagher Neil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 31,000 | 31,000 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Neil Gallagher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 74,000 | 74,000 | - | - | Stock Option (Right to Buy) | |
| Syndax Pharmaceuticals Inc | Gallagher Neil | President, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 69,375 | 69,375 | - | - | Stock Options (Right to buy) | |
| Syndax Pharmaceuticals Inc | Gallagher Neil | President, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 34,688 | 34,688 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Neil Gallagher | President, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2024 | 13,125 | 47,813 (0%) | 0% | 0 | Common Stock | |
| Syndax Pharmaceuticals Inc | Neil Gallagher | President, Head of R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 250,000 | 250,000 | - | - | Stock Options (Right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges